[Subconjunctival injection of bevacizumab for treatment of corneal neovascularization after perforating keratoplasty].
Maier
M M
MM
Augenklinik der Technischen Universität München, Klinikum rechts der Isar. M.Maier@lrz.tum.de
Erben
A
A
Khoramnia
R
R
Zapp
D
D
Winkler von Mohrenfels
C
C
Lohmann
C
C
D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003228:Conjunctiva / Q000187:drug effects; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D006801:Humans; D007267:Injections; D015948:Keratoplasty, Penetrating / Q000009:adverse effects*; D008297:Male; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab